Study Conduct

Certara, Paidion Research partner on pediatric drug development

Friday, September 11, 2015

Certara, a global biosimulation technology-enabled drug development company, and Paidion Research, a Durham, N.C.-based pediatric CRO, have partnered to promote more efficient and reliable drug development for pediatric patients. The partnership harnesses Certara’s biosimulation (modeling and simulation) and regulatory writing capabilities with Paidion’s regulatory strategy and pediatric clinical trial management expertise to address the critical challenges of bringing new therapies to children.

[Read More]

goBalto joins SCRS as GIP

Wednesday, September 9, 2015

San Francisco-based goBalto, a provider of cloud-based clinical study startup solutions, has announced a two-year partnership with the Society for Clinical Research Sites (SCRS), a global trade organization fully dedicated to representing the interests of clinical research sites. goBalto will participate as a Global Impact Partner (GIP), a relationship designed to facilitate critical dialogue between industry stakeholders and clinical research sites.

[Read More]

Icon applies IBM Watson Clinical Trial Matching

Wednesday, September 9, 2015

Icon, a global CRO, is working with IBM to help reduce the time and costs of drug development, while also offering patients enhanced quality-of-care by connecting them to relevant clinical trials. Icon will tap Watson’s cognitive computing power to help automate the cumbersome process of identifying patients who meet the criteria for a clinical trial, and to analyze protocols to assess trial feasibility and identify optimal trial sites.

[Read More]

U.K. approves informed consent technology

Tuesday, September 8, 2015

With a goal of pushing aside paper-based informed clinical trial consents and providing an electronic informed consent system, California-based Mytrus and an unnamed Top 10 pharmaceutical company are set to become the first organizations cleared to use eConsent technology in the U.K.

[Read More]